Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Apr 22:25:2950-2958.
doi: 10.12659/MSM.916305.

Intralesional Injection of Botulinum Toxin Type A Compared with Intralesional Injection of Corticosteroid for the Treatment of Hypertrophic Scar and Keloid: A Systematic Review and Meta-Analysis

Minglei Bi  1 , Pengfei Sun  1 , Danyi Li  1 , Zheng Dong  1 , Zhenyu Chen  1
Affiliations
Meta-Analysis

Intralesional Injection of Botulinum Toxin Type A Compared with Intralesional Injection of Corticosteroid for the Treatment of Hypertrophic Scar and Keloid: A Systematic Review and Meta-Analysis

Minglei Bi et al. Med Sci Monit. .

Abstract

BACKGROUND The optimal treatment for hypertrophic scar and keloid remains controversial. Therefore, the aim of this systematic review and meta-analysis was to compare the effectiveness of intralesional injection of botulinum toxin type A compared with placebo and intralesional injection of corticosteroid compared with placebo in patients with hypertrophic scar and keloid. MATERIAL AND METHODS Six databases were searched using Medical Subject Headings (MeSH) keywords and included Web of Science, PubMed, EMBASE, the Cochrane Library, WanFang, and CNKI from their inception to March 1 2019, without language restriction. Randomized controlled trials (RCTs) and prospective controlled trials (PCTs) were identified that compared intralesional injection of botulinum toxin type A with placebo and corticosteroid with placebo in hypertrophic scar and keloid. The quality of controlled trials was assessed by the Newcastle-Ottawa Scale (NOS). RESULTS Comparison of intralesional botulinum toxin type A and corticosteroid showed significant differences in the Visual Analog Scale (VAS) (P<0.001) (WMD, -4.30; 95% CI, -4.44 to -4.16) and effective rate (P=0.012) (RR=0.82; 95% CI, 0.70-0.96). Intralesional injection of botulinum toxin type A compared with placebo showed significant differences in the VAS (P<0.001) (WMD, 1.41; 95% CI, 1.21-1.62), the width of scar (P=0.00) (WMD, -0.15; 95% CI, -0.19 to -0.10) and Vancouver Scar Scale (VSS) (P=0.003) (WMD, -0.69; 95% CI, -1.14 to -0.23). CONCLUSIONS Systematic review and meta-analysis showed that injection of intralesional botulinum toxin type A was more effective in the treatment of hypertrophic scar and keloid than injection of intralesional corticosteroid or placebo.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

None.

Figures

Figure 1
Figure 1
Flow diagram of the systematic review of the literature and selection of studies to compare intralesional injection of botulinum toxin type A compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid.
Figure 2
Figure 2
Forest plot to compare the visual analog scale (VAS) findings between the group treated with intralesional injection of botulinum toxin type A and the placebo group.
Figure 3
Figure 3
Forest plot to compare the visual analog scale (VAS) findings between the group treated with intralesional injection of botulinum toxin type A and the group treated with intralesional injection of corticosteroid.
Figure 4
Figure 4
Forest plot to compare the Vancouver Scar Scale (VSS) findings between the group treated with intralesional injection of botulinum toxin type A and the placebo group.
Figure 5
Figure 5
Forest plot to compare the effectiveness rate between the group treated with intralesional injection of botulinum toxin type A and the group treated with intralesional injection of corticosteroid.
Figure 6
Figure 6
Forest plot to compare the width of the scar between the group treated with intralesional injection of botulinum toxin type A and the placebo group.
See this image and copyright information in PMC

References

    1. Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: A useful guide. Burns. 2014;40:1255–66. - PMC - PubMed
    1. Gauglitz GG. Management of keloids and hypertrophic scars: Current and emerging options. Clin Cosmet Investig Dermatol. 2013;6:103–14. - PMC - PubMed
    1. Nast A, Eming S, Fluhr J, et al. German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids) J Dtsch Dermatol Ges. 2012;10(10):747–62. - PubMed
    1. Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg. 2010;125:557–68. - PubMed
    1. Wolfram D, Tzankov A, Pülzl P, Piza-Katzer H. Hypertrophic scars and keloids – a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg. 2009;35:171–81. - PubMed

MeSH terms

Substances